1 Min Read
Sept 3 (Reuters) - GlaxoSmithKline Plc :
* Triumeq receives EU approval
* ViiV Healthcare receives EU marketing authorisation for Triumeq, a new once-daily single-pill regimen for treatment of HIV Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.